Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
المؤلفون المشاركون
Richter, James M.
Arshi, Nabeela K.
Oster, Gerry
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-04-12
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background.
Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate (“5-ASA”), mesalamine suppository, or mesalamine enema (“UP Rx”).
Little is known about their effectiveness in practice.
Methods.
Using a US health insurance database, we identified new-onset UP patients between January 1, 2005, and December 31, 2007, based on the following: (1) initiation of UP Rx; (2) endoscopy in prior 30 days resulting in diagnosis of UP; and (3) no prior encounters for ulcerative colitis or Crohn’s disease.
We examined the incidence of therapy escalation and total costs in relation to initial UP Rx.
Results.
We identified 548 patients: 327 received mesalamine suppository, 138 received oral 5-ASA, and 83 received mesalamine enema, as initial UP Rx.
One-third receiving oral 5-ASA experienced therapy escalation over 12 months, 21% for both mesalamine suppository and enema.
Mean cumulative total cost of UP Rx over 12 months was $1552, $996, and $986 for patients beginning therapy with oral 5-ASA, mesalamine enema, and mesalamine suppository, respectively.
Contrary to expert recommendations the treatments were often not continued prophylactically.
Conclusions.
Treatment escalation was common, and total costs of therapy were higher, in patients who initiated treatment with oral 5-ASA.
Further study is necessary to assess the significance of these observations.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Richter, James M.& Arshi, Nabeela K.& Oster, Gerry. 2016. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. Canadian Journal of Gastroenterology and Hepatology،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1099906
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Richter, James M.…[et al.]. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. Canadian Journal of Gastroenterology and Hepatology No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1099906
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Richter, James M.& Arshi, Nabeela K.& Oster, Gerry. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. Canadian Journal of Gastroenterology and Hepatology. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1099906
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1099906
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر